These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2494462)

  • 41. Dose-effect relationship estimation for thrombolytic therapy in acute myocardial infarction.
    Boissel JP; Leizorovicz A; Peyrieux JC
    Semin Thromb Hemost; 1987 Apr; 13(2):181-5. PubMed ID: 3114886
    [No Abstract]   [Full Text] [Related]  

  • 42. Thrombolysis in coronary occlusion--the full circle.
    Bauer GE
    Aust N Z J Med; 1989 Apr; 19(2):85-7. PubMed ID: 2504138
    [No Abstract]   [Full Text] [Related]  

  • 43. Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings.
    Hellstern P; Doenecke P; Köhler M; Schwerdt H; Ozbek C; Miyashita C; Bette L; Wenzel E
    Drugs; 1987; 33 Suppl 3():183-5. PubMed ID: 3315589
    [No Abstract]   [Full Text] [Related]  

  • 44. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Efficacy data.
    Chamberlain DA
    Drugs; 1987; 33 Suppl 3():221-2. PubMed ID: 3315596
    [No Abstract]   [Full Text] [Related]  

  • 45. Thrombolytic therapy.
    N Engl J Med; 1988 Dec; 319(23):1543-7. PubMed ID: 3141813
    [No Abstract]   [Full Text] [Related]  

  • 46. [Home thrombolysis in the acute stage of myocardial infarction].
    Herve C; Gaillard M; Gabe JL; Goulois R; Mercadal L; Marchadier C
    Presse Med; 1987 Apr; 16(14):682-3. PubMed ID: 2952999
    [No Abstract]   [Full Text] [Related]  

  • 47. Tenecteplase: single-bolus thrombolytic therapy for acute myocardial infarction.
    McGahan L
    Issues Emerg Health Technol; 2001 Jan; (13):1-6. PubMed ID: 11902221
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results.
    Lenhoff SJ; Horak AR; Fraser RC; Scott-Millar RN; Bird AR; Jacobs P; Commerford PJ
    Drugs; 1987; 33 Suppl 3():186-8. PubMed ID: 3315590
    [No Abstract]   [Full Text] [Related]  

  • 49. [Thrombolytic treatment for acute myocardial infarction].
    Tranchesi Júnior B
    AMB Rev Assoc Med Bras; 1989; 35(4):159-63. PubMed ID: 2518083
    [No Abstract]   [Full Text] [Related]  

  • 50. [Acyl enzymes and pro-urokinase: promising new thrombolytic agents].
    Samama M; Horellou MH; Nguyen G; Conard J
    Haemostasis; 1986; 16 Suppl 4():35-9. PubMed ID: 3095199
    [No Abstract]   [Full Text] [Related]  

  • 51. The APSAC interventional mortality study (AIMS) trial: mortality data.
    Julian DG
    Clin Cardiol; 1990 Mar; Suppl 5():V20-1; discussion V27-32. PubMed ID: 2182236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Tolerance data.
    Chamberlain DA
    Drugs; 1987; 33 Suppl 3():286. PubMed ID: 3315609
    [No Abstract]   [Full Text] [Related]  

  • 53. Thrombolytic therapy in acute myocardial infarction: an overview (continuing education credit).
    Henderson E
    J Emerg Nurs; 1989; 15(2( Pt 2)):145-51. PubMed ID: 2495375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction.
    Hillis WS; Hornung RS
    Eur Heart J; 1985 Nov; 6(11):909-12. PubMed ID: 3908105
    [No Abstract]   [Full Text] [Related]  

  • 55. Biochemical and pharmacologic comparison of thrombolytic agents.
    Stringer KA
    Pharmacotherapy; 1996; 16(5 Pt 2):119S-126S. PubMed ID: 8888099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [At home thrombolysis. 100 cases].
    Hervé C; Gaillard M; Castaigne A; Jan F; Huguenard P
    Presse Med; 1988 Dec; 17(43):2308. PubMed ID: 2974965
    [No Abstract]   [Full Text] [Related]  

  • 57. Eligibility for thrombolytic therapy in acute myocardial infarction.
    Jagger JD; Murray RG; Davies MK; Littler WA; Flint EJ
    Lancet; 1987 Jan; 1(8523):34-5. PubMed ID: 2879104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction.
    Hoffmann JJ; Van Rey FJ; Bonnier JJ
    Thromb Res; 1985 Mar; 37(5):567-72. PubMed ID: 3920779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of myocardial infarction in the community: a new RCGP study.
    Kay C
    Br J Gen Pract; 1991 Mar; 41(344):89-90. PubMed ID: 1903264
    [No Abstract]   [Full Text] [Related]  

  • 60. Should we intervene following thrombolytic therapy? The SWIFT study in progress. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():229-30. PubMed ID: 3315599
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.